Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs

Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs

HONG KONG, Feb. 25, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer Inc....

Pfizer Receives Authorization from Health Authority for Its 20-valent Pneumococcal Conjugate Vaccine for Infants and Children

Pfizer Receives Authorization from Health Authority for Its 20-valent Pneumococcal Conjugate Vaccine for Infants and Children

In Hong Kong, the 20-valent Pneumococcal Conjugate Vaccine (PCV20) that offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine – helping to fight against 20 serotypes leading to most of the invasive pneumococcal...

Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Hong Kong

Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Hong Kong

SHANGHAI, Dec. 2, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today...

menu
menu